FOXM1 and cancer: Recently, studies have demonstrated the involvement of FOXM1 in chemoresistance [12], and several FOXM1-targeting small molecule compounds, such as Siomycin A plus 5-FU [22], Thiostrepton plus Selumetinib [56], and FDI-6 plus PARP inhibitor Olaparib [57], have been tested in combination therapy to overcome drug resistance in cancer treatment.